Evidence map›Paper›PMID 34129427›Full record

ReviewInternational journal of radiation biology2022

All for one, though not one for all: team players in normal tissue radiobiology.

Marjan Boerma, Catherine M Davis, Isabel L Jackson, Dörthe Schaue, Jacqueline P Williams

Abstract readReview
In one paragraph

Review in International journal of radiation biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Curcumin's Radioprotective Effects on Zebrafish Embryos.Antioxidants (Basel, Switzerland) · 2024
    Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marjan BoermaDivision of Radiation Health, University of Arkansas for Medical Sciences, Little Rock, AR, USA.ORCID 0000-0003-2249-5203
Catherine M DavisDepartment of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.ORCID 0000-0002-2591-6352
Isabel L JacksonDivision of Translational Radiation Sciences, Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-2998-7606
Dörthe SchaueDepartment of Radiation Oncology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-5674-678X
Jacqueline P WilliamsDepartment of Environmental Medicine, University of Rochester Medical Center, Rochester, NY, USA.ORCID 0000-0002-5635-1526

Funding

The Role o f Tetrahydrobiopterin (BH4) Bioavailability in Radiation-induced Skin InjuryP20GM109005 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI BOERMA, MARJAN · 2015 to 2024
$21.1M
Preclinical Evaluation of Radioprotectin-1 for Mitigation of GI-ARSU19AI150574 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI OKUNIEFF, PAUL · 2020 to 2024
$13.0M
The Protein C Pathway in Mitigation of Radiation-Induced Endothelial and Vascular DysfunctionU01AI133561 · NIAID · UNIV OF ARKANSAS FOR MED SCIS · PI BOERMA, MARJAN, GRIFFIN, JOHN H · 2017 to 2021
$3.3M
Project-002U01AI148308 · NIAID · UNIV OF ARKANSAS FOR MED SCIS · PI BOERMA, MARJAN, CHEEMA, AMRITA KAUR · 2020 to 2024
$2.8M
Acute radiation injury alters microRNA profiles that predict late tissue-specific damageU01AI148322 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SCHAUE, DORTHE · 2020 to 2024
$2.4M
Germ-line miRNA binding site variants as biomarkers of toxicity and response to checkpoint inhibitionR01CA238998 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WEIDHAAS, JOANNE B · 2019 to 2023
$1.8M
Myeloid reprogramming in response to acute radiation tissue damageR01CA226875 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SCHAUE, DORTHE · 2019 to 2023
$1.8M
Cellular Basis for Radiation induced acceleration of sarcopenia in juvenile cancer survivorsR01CA220467 · NCI · UNIVERSITY OF ROCHESTER · PI CHAKKALAKAL, JOE · 2017 to 2021
$1.8M
R01 Transfer from U. of Rochester- Lactate Promotes Scarring After IrradiationR01HL127001 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI SIME, PATRICIA JANET, WILLIAMS, JACQUELINE PATRICIA · 2016 to 2019
$1.5M
Visualizing radiation-induced tumor immune responsesR21CA228542 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI SCHAUE, DORTHE, WU, ANNA M · 2019 to 2020
$416k
Development of a novel therapy for mitigation of the irradiation-inducedgastrointestinal syndromeR44AI138865 · NIAID · BIOINCEPT, LLC · PI BARNEA, EYTAN R · 2019 to 2019
$207k
NCI NIH HHS R01 CA220467NCI NIH HHS R01 CA226875NCI NIH HHS R01 CA238998NCI NIH HHS R21 CA228542NHLBI NIH HHS R01 HL127001NIAID NIH HHS R44 AI138865NIAID NIH HHS U01 AI133561NIAID NIH HHS U01 AI148308NIAID NIH HHS U01 AI148322NIAID NIH HHS U19 AI150574NIGMS NIH HHS P20 GM109005Shared Services Center NASA 80NSSC18K0542Shared Services Center NASA 80NSSC18K1080Shared Services Center NASA 80NSSC19K0542
6 · The paper itself

Abstract

purposeAs part of the special issue on 'Women in Science', this review offers a perspective on past and ongoing work in the field of normal (non-cancer) tissue radiation biology, highlighting the work of many of the leading contributors to this field of research. We discuss some of the hypotheses that have guided investigations, with a focus on some of the critical organs considered dose-limiting with respect to radiation therapy, and speculate on where the field needs to go in the future.

conclusionsThe scope of work that makes up normal tissue radiation biology has and continues to play a pivotal role in the radiation sciences, ensuring the most effective application of radiation in imaging and therapy, as well as contributing to radiation protection efforts. However, despite the proven historical value of preclinical findings, recent decades have seen clinical practice move ahead with altered fractionation scheduling based on empirical observations, with little to no (or even negative) supporting scientific data. Given our current appreciation of the complexity of normal tissue radiation responses and their temporal variability, with tissue- and/or organ-specific mechanisms that include intra-, inter- and extracellular messaging, as well as contributions from systemic compartments, such as the immune system, the need to maintain a positive therapeutic ratio has never been more urgent. Importantly, mitigation and treatment strategies, whether for the clinic, emergency use following accidental or deliberate releases, or reducing occupational risk, will likely require multi-targeted approaches that involve both local and systemic intervention. From our personal perspective as five 'Women in Science', we would like to acknowledge and applaud the role that many female scientists have played in this field. We stand on the shoulders of those who have gone before, some of whom are fellow contributors to this special issue.

Indexed as

NeoplasmsRadiation ProtectionFemaleHumansRadiobiologybraincardiovascular systemimmune systemlungNormal tissue radiobiology

Identifiers

PMID34129427
PMCPMC8781287

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.